NOBIAS THERAPEUTICS
Nobias Therapeutics is a developer of rare pediatric disease drugs intended to cure rare illnesses in children. It focuses on discovering the genetic basis for rare diseases and develops drugs that can intervene in the affected pathways, enabling parents to help their infants become healthier.
NOBIAS THERAPEUTICS
Industry:
Health Care Medical Therapeutics
Address:
Princeton, New Jersey, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
3.75 M USD
Similar Organizations
Empirica Therapeutics
Empirica Therapeutics is a developer of therapeutic drugs designed to treat aggressive forms of cancer.
Genase Therapeutics
Genase Therapeutics is the developer of therapeutic products intended to treat solid tumors.
Pharmetrics
Pharmetrics provides a collaborative approach to create medications tailored to the therapeutic needs of individual patients.
PowderMed
PowderMed developed the Particle Mediated Epidermal Delivery (PMED) technology.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Spokane Therapist
Spokane Therapist is a dedicated group of mental health professions serving the Spokane community with compassion and empathetic care.
Theranostec
Theranostec is a developer of effective and safe anti-cancer therapies.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Validus Cellular Therapeutics
Validus Cellular Therapeutics is a developer of therapeutic solutions for treating infectious diseases.
Wings Therapeutics
Wings Therapeutics is a developer of genetic skin disease drug designed to improve the healing and integrity of the skin.
Current Employees Featured
Investors List
Domain Associates
Domain Associates investment in Series A - Nobias Therapeutics
More informations about "Nobias Therapeutics"
Nobias Therapeutics – Home
Nobias Therapeutics is a clinical-stage company leveraging unique genomic and health record data to develop novel therapeutics for rare pediatric diseases.See details»
Nobias Therapeutics - About
Nobias Therapeutics is a clinical-stage company leveraging unique genomic and health record data to develop novel therapeutics for rare pediatric diseases.See details»
Nobias Therapeutics - Crunchbase Company Profile
Nobias Therapeutics is a developer of rare pediatric disease drugs intended to cure rare illnesses in children. It focuses on discovering the genetic basis for …See details»
Nobias Therapeutics Company Profile 2024: Valuation, …
Developer of a pediatrics-first biotechnology company intended to focus on genetically-defined rare diseases.See details»
Mitsubishi Tanabe Pharma America and Nobias Therapeutics …
Sep 4, 2024 · Nobias’ proprietary AI technology, the Nobias Workbench™, distills disease drivers and optimal points for therapeutic intervention from rich clinical and genetic datasets. Under …See details»
Press Release - Nobias Therapeutics
MOUNTAIN VIEW, CA, AND PHILADELPHIA, PA – Oct 10th, 2023 – Nobias Therapeutics, a biotechnology company pioneering AI-based deep phenotyping techniques to discover …See details»
Nobias Therapeutics - LinkedIn
Nobias is currently running a phase 2 clinical trial for treating symptoms of anxiety, inattention, and autism in children with 22q11 deletion syndrome.See details»
Nobias Therapeutics Announces Strategic Focus and New …
Nov 14, 2024 · Nobias Therapeutics, a clinical-stage company developing novel small-molecule therapeutics for rare diseases, has announced its intent to focus its resources on its …See details»
Nobias Therapeutics - VentureRadar
Develops a drug discovery platform utilizing Artificial Intelligence, Machine Learning, and unique databases to identify rare pediatric disease treatments, enabling rapid pre-clinical testing and …See details»
Nobias Therapeutics - Funding, Financials, Valuation & Investors
Nobias Therapeutics is a developer of rare pediatric disease drugs intended to cure rare illnesses in children.See details»
Nobias Therapeutics Announces Acceptance Of Late …
Sep 20, 2023 · Nobias Therapeutics, a biotechnology company pioneering AI-based deep phenotyping techniques to discover advanced therapeutics, today announced new results.See details»
Press Release - Nobias Therapeutics
Sep 20, 2023 · Nobias Therapeutics is a biotechnology company pioneering deep phenotyping to discover advanced therapeutics. Nobias uses its cutting-edge, applied AI platform to distill …See details»
Nobias Therapeutics Announces Phase 2 Clinical Trial Results for …
Oct 10, 2023 · MOUNTAIN VIEW, Calif., AND PHILADELPHIA, Oct. 10, 2023 /PRNewswire-PRWeb/ -- Nobias Therapeutics, a biotechnology company pioneering AI-based deep …See details»
Series A - Nobias Therapeutics - 2020-07-24 - Crunchbase
Jul 24, 2020 · Organization Name . Nobias Therapeutics . Announced Date Jul 24, 2020; Funding Type Series A; Funding Stage Early Stage ... Domain Associates — Recent News. Edit …See details»
Fasoracetam - Nobias Therapeutics - AdisInsight
Oct 17, 2023 · Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.See details»
Nobias Therapeutics - Pipeline
Nobias Therapeutics is a clinical-stage company leveraging unique genomic and health record data to develop novel therapeutics for rare pediatric diseases.See details»
Nobias Therapeutics Company Profile - Office Locations ... - Craft
Nobias Therapeutics is a biotechnology company that develops deep phenotyping techniques to discover therapeutics. It uses AI and machine learning-based (ML) tools to develop an …See details»
Nobias Therapeutics - Contacts, Employees, Board Members
Nobias Therapeutics is a developer of rare pediatric disease drugs intended to cure rare illnesses in children.See details»
Nobias Therapeutics - News & Events
Sep 20, 2023 · Nobias Therapeutics Announces Strategic Focus and New Leadership November 14, 2024. Nobias Therapeutics Joins NVIDIA Inception Program for Startups April 16, 2024. …See details»
J. Patrick Dougherty - Consulting COO @ Nobias Therapeutics ...
Before joining Nobias, Dougherty established Beech Street Advisors, LLC, a biotech advisory practice supporting early-stage therapeutic companies by providing hands-on, functional …See details»